Nuvation Bio (NYSE:NUVB) Director Robert Mashal Purchases 25,000 Shares

Nuvation Bio Inc. (NYSE:NUVB) Director Robert Mashal bought 25,000 shares of Nuvation Bio stock in a transaction dated Tuesday, June 9th. The stock was purchased at an average price of $4.73 per share, for a total transaction of $118,250.00. Following the purchase, the director directly owned 225,000 shares in the company, valued at $1,064,250. This represents a 12.50% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Nuvation Bio Stock Up 4.3%

Shares of NYSE:NUVB opened at $4.78 on Friday. Nuvation Bio Inc. has a 52 week low of $1.57 and a 52 week high of $9.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.24 and a current ratio of 7.44. The company’s fifty day moving average is $4.72 and its 200-day moving average is $5.89. The company has a market capitalization of $1.66 billion, a PE ratio of -11.10 and a beta of 1.52.

Nuvation Bio (NYSE:NUVB) last issued its earnings results on Monday, May 4th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The company had revenue of $83.23 million for the quarter, compared to the consensus estimate of $66.22 million. Equities research analysts predict that Nuvation Bio Inc. will post -0.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NUVB has been the topic of several recent analyst reports. UBS Group reduced their target price on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 3rd. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research note on Tuesday, May 5th. Royal Bank Of Canada restated an “outperform” rating and issued a $20.00 target price on shares of Nuvation Bio in a research note on Tuesday, May 5th. HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Nuvation Bio in a research note on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a research note on Tuesday, April 21st. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Nuvation Bio currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Nuvation Bio by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company’s stock worth $139,378,000 after buying an additional 101,011 shares in the last quarter. Millennium Management LLC lifted its position in Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after buying an additional 1,298,131 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Nuvation Bio by 19.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock worth $12,276,000 after buying an additional 551,508 shares in the last quarter. Aisling Capital Management LP lifted its position in Nuvation Bio by 16.5% during the 3rd quarter. Aisling Capital Management LP now owns 2,960,659 shares of the company’s stock worth $10,954,000 after buying an additional 419,650 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Nuvation Bio by 852.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock worth $24,270,000 after buying an additional 2,424,109 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.